Search Results - "Gershanik, Oscar S."

Refine Results
  1. 1

    Improving l-dopa therapy: The development of enzyme inhibitors by Gershanik, Oscar S.

    Published in Movement disorders (01-01-2015)
    “…ABSTRACT The introduction of levodopa produced a monumental change in the treatment of Parkinson's disease (PD). Limitations in its bioavailability and…”
    Get full text
    Journal Article
  2. 2

    Postural deformities in Parkinson's disease by Doherty, Karen M, MRCP, van de Warrenburg, Bart P, MD, Peralta, Maria Cecilia, MD, Silveira-Moriyama, Laura, PhD, Azulay, Jean-Philippe, Prof, Gershanik, Oscar S, MD, Bloem, Bastiaan R, Prof

    Published in Lancet neurology (01-06-2011)
    “…Summary Postural deformities are frequent and disabling complications of Parkinson's disease (PD) and atypical parkinsonism. These deformities include…”
    Get full text
    Journal Article
  3. 3

    Does Parkinson's disease start in the gut? by Gershanik, Oscar S

    Published in Arquivos de neuro-psiquiatria (01-02-2018)
    “…Current understanding of the pathophysiology of Parkinson's disease suggests a key role of the accumulation of alpha-synuclein in the pathogenesis. This…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7

    Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism by Larramendy, Celia, Taravini, Irene R.E., Saborido, Mariano D., Ferrario, Juan E., Murer, Mario G., Gershanik, Oscar S.

    Published in Behavioural brain research (01-12-2008)
    “…Levodopa-induced dyskinesias are one of the major limiting side effects encountered in the treatment of Parkinson's disease. Dopamine agonists of the D2 family…”
    Get full text
    Journal Article
  8. 8

    Pleiotrophin over-expression provides trophic support to dopaminergic neurons in parkinsonian rats by Taravini, Irene Re, Chertoff, Mariela, Cafferata, Eduardo G, Courty, José, Murer, Mario G, Pitossi, Fernando J, Gershanik, Oscar S

    Published in Molecular neurodegeneration (07-06-2011)
    “…Pleiotrophin is known to promote the survival and differentiation of dopaminergic neurons in vitro and is up-regulated in the substantia nigra of Parkinson's…”
    Get full text
    Journal Article
  9. 9

    Dancing Dorsal Quadrilaterals: A Novel Peripherally Induced Movement Disorder by Lizarraga, Karlo J, Thompson, Philip D, Moore, Henry P, Mizraji, Gabriel, Gershanik, Oscar S, Singer, Carlos, Lang, Anthony E

    Published in JAMA neurology (01-03-2019)
    “…Recognized peripherally induced movement disorders include the painful legs moving toes syndrome, postamputation dyskinesias, and belly dancer dyskinesias. To…”
    Get more information
    Journal Article
  10. 10

    Clinical problems in late-stage Parkinson’s disease by Gershanik, Oscar S.

    Published in Journal of neurology (01-11-2010)
    “…Advanced Parkinson’s disease patients require for their care the participation of a multidisciplinary team. Particularly in the late stages of the disease,…”
    Get full text
    Journal Article
  11. 11

    Subjective visual vertical in Pisa syndrome by Scocco, Darío H, Wagner, Judith N, Racosta, Juan, Chade, Anabel, Gershanik, Oscar S

    Published in Parkinsonism & related disorders (01-08-2014)
    “…Abstract Background Parkinson's Disease (PD) alters perception and somatosensory information integration, including visual dependency and judgment of body…”
    Get full text
    Journal Article
  12. 12

    The Kinase Fyn As a Novel Intermediate in l-DOPA-Induced Dyskinesia in Parkinson’s Disease by Sanz-Blasco, Sara, Bordone, Melina P., Damianich, Ana, Gomez, Gimena, Bernardi, M. Alejandra, Isaja, Luciana, Taravini, Irene R., Hanger, Diane P., Avale, M. Elena, Gershanik, Oscar S., Ferrario, Juan E.

    Published in Molecular neurobiology (01-06-2018)
    “…Dopamine replacement therapy with l -DOPA is the treatment of choice for Parkinson’s disease; however, its long-term use is frequently associated with l…”
    Get full text
    Journal Article
  13. 13

    Regulation of Pleiotrophin and Fyn in the striatum of rats undergoing L-DOPA-induced dyskinesia by Gomez, Gimena, Saborido, Mariano D., Bernardi, M. Alejandra, Gershanik, Oscar S., Taravini, Irene R., Ferrario, Juan E.

    Published in Neuroscience letters (14-02-2018)
    “…•Striatal Pleiotrophin immunodetection is increased in L-DOPA induced dyskinesias.•Total amounts of the kinase Fyn are unchanged by 6-OHDA lesion or…”
    Get full text
    Journal Article
  14. 14
  15. 15

    Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease by Taravini, Irene R., Larramendy, Celia, Gomez, Gimena, Saborido, Mariano D., Spaans, Floor, Fresno, Cristóbal, González, Germán A., Fernández, Elmer, Murer, Mario G., Gershanik, Oscar S.

    Published in Neuropharmacology (01-02-2016)
    “…Whether the treatment of Parkinson's disease has to be initiated with levodopa or a D2 agonist like pramipexole remains debatable. Levodopa is more potent…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process by Ferrario, Juan E., Delfino, Marina A., Stefano, Andrea V., Zbarsky, Virginia, Douhou, Aicha, Murer, M.Gustavo, Raisman-Vozari, Rita, Gershanik, Oscar S.

    Published in Neuroscience research (01-12-2003)
    “…Although the issue of in vivo levodopa toxicity appears to be settled by now in the light of recent findings, a crucial aspect was not accounted for the…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Typical and atypical neuroleptics by Gershanik, Oscar S, Gómez Arévalo, Gonzalo J

    Published in Handbook of clinical neurology (2011)
    “…Neuroleptics having dopamine receptor-blocking properties are frequently responsible for the development of movement disorders. This has been known for many…”
    Get more information
    Journal Article
  20. 20